Razuprotafib

SKU: orb1307812

Description

Razuprotafib

Research Area

Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 1008510-37-9
• MW: 586.7
• Purity: 95.93% (May vary between batches)
• Formula: C₂₆H₂₆N₄O₆S₃
• SMILES: COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(n1)-c1cccs1
• Target: Phosphatase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (6.82 mM);DMSO:100 mg/mL (170.44 mM)

Bioactivity

• Target IC50:
  HPTPß:50 nM
• In Vivo:
  Rho-VEGF–transgenic mice s.c. injection 20 mg/kg 12 hours promotes phosphorylation of TIE2 in retinal endothelial cells Rho-VEGF mice s.c. injection 10-20 mg/kg twice daily for 7 days suppresses subretinal neovascularization.
  Read more...
• In Vitro:
  Razuprotafib inhibits the phosphatase activity of VE-PTP with an IC50 of 17 pM. Razuprotafib inhibits the phosphatase PTP1B with an IC50 of 780 nM. Razuprotafib inhibits HPTPη (IC50 = 36 pM) . Razuprotafib inhibits HPTPγ (IC50 = 100 pM). Razuprotafib 0.17 to 50 μM HUVEC 10 minutes in WB concentration-dependent phosphorylation of TIE2 and downstream components of the TIE2 signaling pathway, including eNOS, AKT, and ERK.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

acute, AKB 9778, AKB9778, AKB-9778, diabetic, nephropathy, kidney, inhibit, Inhibitor, injury, HPTPß, Tie-2, Razuprotafib, Phosphatase

Compound Identifiers

PubChem CID

46700782